Nervgen Pharma (NGEN) Retained Earnings (2024 - 2026)

Nervgen Pharma (NGEN) has reported Retained Earnings for 3 consecutive years, with -$128.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Retained Earnings changed N/A year-over-year to -$128.4 million in Q2 2026; TTM through Jun 2026 was -$128.4 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$105.2 million, down 40.37% from the prior year.
• Retained Earnings was -$128.4 million for Q2 2026 at Nervgen Pharma, down from -$108.2 million in the prior quarter.
• Over five years, Retained Earnings peaked at -$73.5 million in Q4 2024 and troughed at -$128.4 million in Q2 2026.
• A 3-year average of -$103.8 million and a median of -$106.7 million in 2025 frame the typical range for Retained Earnings.
• The widest YoY moves for Retained Earnings: up 43.23% in 2025, down 43.23% in 2025.
• Over 3 years, Retained Earnings stood at -$73.5 million in 2024, then slumped by 43.23% to -$105.2 million in 2025, then fell by 22.04% to -$128.4 million in 2026.
• The last three Retained Earnings figures came in at -$128.4 million (Q2 2026), -$108.2 million (Q1 2026), and -$105.2 million (Q4 2025), per Business Quant data.